Tardive Dyskinesia and Oxidative Stress

1997 ◽  
pp. 315-324 ◽  
Author(s):  
Jean Lud Cadet
Keyword(s):  
Oxidative Stress ◽  
Tardive Dyskinesia ◽  
And Oxidative Stress

Markers of Glutamatergic Neurotransmission and Oxidative Stress Associated With Tardive Dyskinesia

1998 ◽  
Vol 155 (9) ◽  
pp. 1207-1213 ◽  
Author(s):  
Guochuan Tsai ◽  
Donald C. Goff ◽  
Robert W. Chang ◽  
James Flood ◽  
Lee Baer ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Tardive Dyskinesia ◽  
Glutamatergic Neurotransmission ◽  
And Oxidative Stress

scholarly journals Estrogen Receptor Activation and Tardive Dyskinesia

2000 ◽  
Vol 45 (3) ◽  
pp. 288-290 ◽  
Author(s):  
Peter Turrone ◽  
Mary V Seeman ◽  
Simone Silvestri
Keyword(s):  
Oxidative Stress ◽  
Tardive Dyskinesia ◽  
Estrogen Replacement Therapy ◽  
Cell Damage ◽  
Receptor Activation ◽  
Estrogen Replacement ◽  
Potential Influence ◽  
The Central Nervous System ◽  
And Oxidative Stress

Objective: To undertake a selective review of the epidemiology, etiology, and treatment of tardive dyskinesia (TD), with emphasis on the potential influence of estrogen in its expression. Method: Both Medline and Psycinfo databases were used to search for articles with the following key words: tardive dyskinesia, humans, animals, dopamine, estrogen, estrogen replacement therapy, antioxidants and oxidative stress. Results: The studies reviewed here suggest that estrogen modulates dopamine-mediated behaviours and that it protects against oxidative stress-induced cell damage caused by long-term exposure to antipsychotic medication. Conclusions: Estrogen's multimodal role in the central nervous system may prove useful for the amelioration or prevention of TD. All the evidence suggests that a placebo-controlled, randomized trial with safer forms of estrogen should be conducted in postmenopausal women with TD.

Association between calcitriol and paricalcitol with oxidative stress in patients with hemodialysis

2020 ◽  
pp. 1-8
Author(s):  
Hasan Haci Yeter ◽  
Berfu Korucu ◽  
Elif Burcu Bali ◽  
Ulver Derici
Keyword(s):  
Oxidative Stress ◽  
Vitamin D ◽  
Antioxidant Status ◽  
Total Antioxidant Status ◽  
Stress Index ◽  
Total Oxidant Status ◽  
Vitamin D Analog ◽  
Total Antioxidant ◽  
Oxidant Status ◽  
And Oxidative Stress

Abstract. Background: The pathophysiological basis of chronic kidney disease and its complications, including cardiovascular disease, are associated with chronic inflammation and oxidative stress. We investigated the effects of active vitamin D (calcitriol) and synthetic vitamin D analog (paricalcitol) on oxidative stress in hemodialysis patients. Methods: This cross-sectional study was composed of 83 patients with a minimum hemodialysis vintage of one year. Patients with a history of any infection, malignancy, and chronic inflammatory disease were excluded. Oxidative markers (total oxidant and antioxidant status) and inflammation markers (C-reactive protein and interleukin-6) were analyzed. Results: A total of 47% (39/83) patients were using active or analog vitamin D. Total antioxidant status was significantly higher in patients with using active or analog vitamin D than those who did not use (p = 0.006). Whereas, total oxidant status and oxidative stress index were significantly higher in patients with not using vitamin D when compared with the patients who were using vitamin D preparation (p = 0.005 and p = 0.004, respectively). On the other hand, total antioxidant status, total oxidant status, and oxidative stress index were similar between patients who used active vitamin D or vitamin D analog (p = 0.6; p = 0.4 and p = 0.7, respectively). Conclusion: The use of active or selective vitamin D analog in these patients decreases total oxidant status and increases total antioxidant status. Also, paricalcitol is as effective as calcitriol in decreasing total oxidant status and increasing total antioxidant status in patients with chronic kidney disease.

Sign in / Sign up

Export Citation Format

Share Document